drugset / Trial / NCT04860011

DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance

NCT04860011 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the effect of dapagliflozin compared with metolazone, added to furosemide, on diuresis and decongestion in hospitalised heart failure patients with diuretic resistance, and renal impairment. The primary analysis will be in patients with HFrEF but patients with HFpEF will also be recruited in an ancillary study and included in supplementary analyses.

Timeline

Start
2021-04-27
Primary completion
2022-10-30
Completion
2023-04-03

Outcome

Missed primary endpoint

paper 3.0 (2.5) kg with dapagliflozin compared to 3.6 (2.0) kg with metolazone [mean difference 0.65, 95% confidence interval (CI) -0.12,1.41 kg; P = 0.11]. PMID 37210742 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject Metolazone Small molecule 5 mg —
Subject Metolazone Small molecule 10 mg —

Indications